$诺和诺德(NVO)$ 看来企业界已经把攻克1型糖尿病放在日程上了。

I have to make the comment that the Semma Therapeutics company that was acquired by Vertex in the not-too-distant past, they have announced that they are deploying initially a nonencapsulated raw injection of stem cell-derived beta cells that will call for the use of an immunosuppressive cocktail. So this kind of approach is nice for them to show proof of principle, you might argue, but it's highly unlikely to deliver a product to the market, which is also why they themselves are stating that their next-generation product is using encapsulation.

And I may remind you Pete that we did a development -- a research agreement with Professor Papas and the Procyon company for having the most elegant encapsulation device available for our beta cells, and they are the ones that are now taking into toxicology trials aiming at the second indication being type 1 diabetes for the company. And we hope that maybe celebrate that at the 100-year anniversary, not of insulin in Toronto, but of the Novo Nordisk company.